Product Info-
Necrotic Enteritis -
Related Topics -
Newsroom 
Contact
Organic
Your current program | Recommended program | Benefits |
Organic | Clostridium perfringens type A toxoid + Coccivac-B |
|
Coccivac is a registered trademark of Schering-Plough Animal Health Corporation.
A US poultry company growing 4.60- to 5.50-pound antibiotic-free birds was having NE outbreaks, resulting in mortality ranging from 2% to 10% among affected flocks. The adverse effects of subclinical NE were not known.
Investigators administered Clostridium perfringens type A toxoid at 10 and 18 weeks to nearly 79,900 pullets producing 100,000 offspring weekly.
Offspring also received Coccivac-B at the hatchery to prevent coccidiosis. In control flocks from hens not vaccinated with the NE toxoid, high mortality from NE developed and standard treatment for NE was administered.
- Mortality was significantly less in the group from hens that received Clostridium perfringens type A toxoid compared to controls (Figure 2). The reduction in mortality was as high as 2.5% by the end of the observation period.
- Lowering mortality by even 1% can have a significant impact on production costs. Click here for more information.
Figure 1. Clostridium perfringens type A toxoid significantly lowered mortality in antibiotic-free birds experiencing NE outbreaks.
